Eva Bligt-Lindén
VAP-1 as drug target in inflammation: Structural features determining ligand interactions

Structural features determining ligand interactions
Eva Bligt-Lindén

was born on October 10, 1984 in Vaasa, Finland. She graduated from Åbo Akademi University in 2009 with a Master of Science in Bioscience. This PhD thesis project in Biochemistry has taken place during 2010-2015 under the supervision of Docent Tiina A. Salminen at the Faculty of Science and Engineering.
VAP-1 as drug target in inflammation: Structural features determining ligand interactions

Eva Bligt-Lindén

Biochemistry, Faculty of Science and Engineering
Åbo Akademi University
Turku, Finland
2015
From the Faculty of Science and Engineering, Åbo Akademi University & National Doctoral Programme in Informational and Structural Biology

**Supervised by:**
Docent Tiina A. Salminen, PhD  
Faculty of Science and Engineering  
Åbo Akademi University  
Turku, Finland

**Reviewed by:**
Professor Juha Rouvinen, PhD  
Department of Chemistry  
University of Eastern Finland  
Joensuu, Finland

and

Academy of Finland Research Fellow Lari Lehtiö, PhD  
Faculty of Biochemistry and Molecular Medicine  
University of Oulu  
Oulu, Finland

**Opponent:**
Assistant Professor Maria Luisa Di Paolo, PhD  
Department of Molecular Medicine  
University of Padova  
Padova, Italy

Cover, from left: Electron density map of pyridazinone inhibitor 13 bound to human VAP-1, figure adapted from publication I. Protein crystals produced and photographed by Dr. Lesa Offermann. Phylogenetic tree of the copper amine oxidases, figure made by Leonor Lopes de Carvalho.

ISBN 978-952-12-3306-7  
Painosalama Oy – Turku, Finland 2015
Somewhere, something incredible is waiting to be known.

-Carl Sagan
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>SAMMANFATTNING</td>
<td>3</td>
</tr>
<tr>
<td>LIST OF ORIGINAL PUBLICATIONS</td>
<td>5</td>
</tr>
<tr>
<td>CONTRIBUTIONS OF THE AUTHOR</td>
<td>6</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>7</td>
</tr>
<tr>
<td>ABBREVIATIONS</td>
<td>10</td>
</tr>
<tr>
<td>1. INTRODUCTION</td>
<td>11</td>
</tr>
<tr>
<td>2. REVIEW OF THE LITERATURE</td>
<td>12</td>
</tr>
<tr>
<td>2.1 Amine oxidases</td>
<td>12</td>
</tr>
<tr>
<td>2.2 CAOs</td>
<td>12</td>
</tr>
<tr>
<td>2.2.1 DAO (the AOC1 gene product)</td>
<td>13</td>
</tr>
<tr>
<td>2.2.2 RAO (the AOC2 gene product)</td>
<td>13</td>
</tr>
<tr>
<td>2.2.3 VAP-1 (the AOC3 gene product)</td>
<td>13</td>
</tr>
<tr>
<td>2.2.4 SAO (the AOC4 gene product)</td>
<td>14</td>
</tr>
<tr>
<td>2.3 The TPQ cofactor and the reaction mechanism of CAOs</td>
<td>14</td>
</tr>
<tr>
<td>2.4 Structure of VAP-1</td>
<td>16</td>
</tr>
<tr>
<td>2.5 Adhesive function of VAP-1</td>
<td>18</td>
</tr>
<tr>
<td>2.6 Extravasation of leukocytes to inflamed tissue</td>
<td>20</td>
</tr>
<tr>
<td>2.7 VAP-1 in inflammatory diseases</td>
<td>20</td>
</tr>
<tr>
<td>2.8 VAP-1 as drug target</td>
<td>22</td>
</tr>
<tr>
<td>2.9.1 Anti-VAP-1 antibodies</td>
<td>23</td>
</tr>
<tr>
<td>2.9.2 Small molecular inhibitors</td>
<td>24</td>
</tr>
<tr>
<td>2.9.3 CAO structures in complex with inhibitors</td>
<td>25</td>
</tr>
<tr>
<td>3. AIMS OF THE STUDY</td>
<td>27</td>
</tr>
<tr>
<td>4. MATERIAL AND METHODS</td>
<td>28</td>
</tr>
</tbody>
</table>
4.1 Crystallography ........................................................................................................... 28
  4.1.1 Extraction of VAP-1 for crystallization (I, II) ..................................................... 28
  4.1.2 Crystallization and diffraction data collection (I, II) ..................................... 28
  4.1.3 Data processing, structure solution and refinement (I, II) ....................... 28
4.2 Activity measurements of VAP-1 activity ................................................................ 29
  4.2.1 Protein expression for activity measurements (I, II) ............................... 29
  4.2.2 Inhibition with imidazole and inhibitors (I, II) ......................................... 29
  4.2.3 Enzyme activity assays for VAP-1 mutants (I) ............................................ 30
4.3 Modeling (II, III, IV) .................................................................................................. 30
4.4 Phylogenetic studies (IV) .......................................................................................... 30
5. RESULTS ...................................................................................................................... 32
  5.1 Serum VAP-1 in complex with imidazole (I) ..................................................... 32
    5.1.1 Serum VAP-1 crystal structure (I) ................................................................. 32
    5.1.2 Identification of a secondary imidazole binding site (I) ............................ 32
    5.1.3 Imidazole inhibits VAP-1 enzymatic activity (I) ....................................... 33
  5.2 Pyridazinone inhibitors of VAP-1 (II) .................................................................. 33
    5.2.1 Potent pyridazinone inhibitors of VAP-1 (II) ........................................... 33
    5.2.2 The inhibitors present a novel binding mode to VAP-1 (II) ................. 34
    5.2.3 The inhibitors show specificity for VAP-1 over other CAOs (II) . 36
    5.2.4 The inhibitors are weak inhibitors of mouse VAP-1 activity (II).. 37
  5.3 Structural comparison of rodent and primate VAP-1 active site (II, III).. 37
    5.3.1 Differences affecting the architecture of the active site (III)............. 37
  5.4 Evolution and functional classification of CAOs (IV) ........................................ 40
    5.4.1 General topology of the CAO phylogenetic tree (IV) ......................... 40
    5.4.2 New insights into the classification of CAOs (IV) ................................. 41
  5.5 VAP-1 to RAO mutations (I, IV) .......................................................................... 44
6. DISCUSSION ................................................................................................................ 46
ABSTRACT

Vascular adhesion protein-1 (VAP-1), which belongs to the copper amine oxidases (CAOs), is a validated drug target in inflammatory diseases. Inhibition of VAP-1 blocks the leukocyte trafficking to sites of inflammation and alleviates inflammatory reactions. In this study, a novel set of potent pyridazinone inhibitors is presented together with their X-ray structure complexes with VAP-1. The crystal structure of serum VAP-1 (sVAP-1) revealed an imidazole binding site in the active site channel and, analogously, the pyridazinone inhibitors were designed to bind into the channel. This is the first time human VAP-1 has been crystallized with a reversible inhibitor and the structures reveal detailed information of the binding mode on the atomic level.

Similarly to some earlier studied inhibitors of human VAP-1, the designed pyridazinone inhibitors bind rodent VAP-1 with a lower affinity than human VAP-1. Therefore, we made homology models of rodent VAP-1 and compared human and rodent enzymes to determine differences that might affect the inhibitor binding. The comparison of the crystal structures of the human VAP-1 and the mouse VAP-1 homology model revealed key differences important for the species specific binding properties. In general, the channel in mouse VAP-1 is more narrow and polar than the channel in human VAP-1, which is wider and more hydrophobic. The differences are located in the channel leading to the active site, as well as, in the entrance to the active site channel. The information obtained from these studies is of great importance for the development and design of drugs blocking the activity of human VAP-1, as rodents are often used for in vivo testing of candidate drugs.

In order to gain more insight into the selective binding properties of the different CAOs in one species a comprehensive evolutionary study of mammalian CAOs was performed. We found that CAOs can be classified into sub-families according to the residues X1 and X2 of the Thr/Ser-X1-X2-Asn-Tyr-Asp active site motif. In the phylogenetic tree, CAOs group into diamine oxidase, retina specific amine oxidase and VAP-1/serum amine oxidase clades based on the
residue in the position X2. We also found that VAP-1 and SAO can be further
differentiated based on the residue in the position X1. This is the first large-scale
comparison of CAO sequences, which explains some of the reasons for the
unique substrate specificities within the CAO family.
SAMMANFATTNING

Vaskulärt adhesionsprotein-1 (VAP-1) tillhör enzymfamiljen kopparhaltiga aminoxidaser (CAO). VAP-1 är involverat i leukocytternas inträde i endotelceller vid inflammation och inhibition av dess funktion har en bevisad antiinflammatorisk verkan. I denna studie presenteras nya typer av VAP-1-pyridazinoninhibitorer. Inhibitorerna är designade att binda till det sekundära imidazolbindningsstället i kanalen som leder fram till det aktiva stället hos VAP-1. Det sekundära imidazolbindningsstället identifierades i samband med strukturbestämningen av serumVAP-1. Detta är den första gången VAP-1 har samkristalliserats med en reversibel inhibitor. Den tredimensionella strukturen beskriver proteinets och inhibitorernas interaktioner på atomnivå.

Trots att dessa inhibitorer uppritar potent och specifik bindning till humant VAP-1 så binder de musens VAP-1 med lägre affinitet. Genom sekvensjämförelser och jämförelse av musens VAP-1-homologimodell med kristallstrukturen av humant VAP-1 kunde artspecifika aminosyraskillnader som orsakar den sämre bindningen hos musens VAP-1 identifieras. Dessa skillnader finns i kanalen som leder till det aktiva stället, samt vid ingången till kanalen. Kanalen som leder till det aktiva stället är bredare och mera hydrofob i humant VAP-1 än kanalen i musens VAP-1, som är smalare och mera polär. Dessa resultat är viktiga vid utvecklingen av nya typspecifika läkemedel mot människans VAP-1 eftersom gnagare ofta används för in vivo-testande av läkemedel.

Hittills har klassificeringen av de olika CAO-familjemedlemmarna varit bristfällig och felaktiga annoteringar har förekommit. I vår evolutionära undersökning av de olika CAO-familjemedlemmarna hos däggdjur kunde vi fastställa ett klassificeringssätt baserat på aminosyrorna X1 och X2 i motivet för det aktiva stället: Thr/Ser-X1-X2-Asn-Tyr-Asp. Diaminoxidas, retina-specifikt aminoxidaser och VAP-1/serumaminoxidas grupperar sig i olika grenar i det fyllogenetiska trädet baserat på aminosyran i position X2. VAP-1 och serumaminoxidas kan ytterligare skiljas åt baserat på aminosyran i position X1.
Detta är den första omfattande evolutionära studien av CAO. Dessa kriterier underlättar en korrekt klassificering av det snabbt ökande antalet nyidentifierade CAOs och resultaten är viktiga vid designen av typspecifika inhibitorer för de olika CAO-familjemedlemmarna.
LIST OF ORIGINAL PUBLICATIONS

This thesis is based on the following original publications, which are referred to by Roman numerals (I-IV) in the text. Publications and figures are reprinted with permission from the publishers.


CONTRIBUTIONS OF THE AUTHOR

The work was designed and manuscripts were written together with the
supervisor. All co-authors contributed to the final manuscripts. Publications II
and III were mainly written by the author.

I. The author participated in the refinement, validation and visualization
of the crystal structures. The author participated in the editing of the text
and pictures in the manuscript.

II. All the X-ray crystallographic studies, including crystallization, data
collection, structure solution, refinement and structure validation, were
performed by the author. Dr. Zbyszek Otwinowski assisted in the
diffraction data processing. The author also performed the homology
modeling.

III. The sequence alignments, homology modeling and structural
comparisons were done by the author.

IV. The author participated in the planning of the work, the analysis of the
results and the writing of the paper together with the supervisor. PhD
student Leonor Lopes de Carvalho performed the study and was mainly
responsible for writing the manuscript.

Additional publications not included in the thesis

Kristiina Aalto, Anu Autio, Elina Kivi, Kati Elima, Yvonne Nymalm, Heli
Elovaara, Tiina Saanijoki, Paul R. Crocker, Mikael Maksimow, Eva Bligt, Tiina
A. Salminen, Marko Salmi, Anne Roivainen and Sirpa Jalkanen. (2011) Siglec-9
is a novel leukocyte ligand for Vascular Adhesion Protein-1 (VAP-1) and can be
utilized in PET-imaging of cancer and inflammation. Blood, 118: 3725-3733

Matti Lahti*, Eva Bligt*, Henri Niskanen, Anna Brandt, Vimal Parkash, Johanna
Jokinen, Pekka Patrikainen, Jarmo Käpylä, Jyrki Heino and Tiina Salminen.
(2011) Structure of the collagen receptor integrin alpha1I domain carrying the
activating mutation E317A. Journal of Biological Chemistry 50: 43343-51 (* equal
contribution)
ACKNOWLEDGEMENTS

This thesis project was carried out in the Structural Bioinformatics Laboratory (SBL) in the Faculty of Science and Engineering, at Åbo Akademi University in Turku during the years 2010-2015. During these years, I have had the opportunity to meet many great people and talented scientists. I would like to thank everyone involved in making this thesis possible.

First I would like to thank, Docent Tiina A. Salminen, and, Professor Mark Johnson, as the two group leaders of the joint SBL for providing a top class crystallography laboratory and excellent computing facilities. I especially want to thank my supervisor, Docent Tiina A. Salminen, for giving me the opportunity to do this thesis in her research group. Thank you for sharing your knowledge, for all the support and guidance. I also want to thank you for introducing me to crystallography and the fascinating world of proteins.

I thank Professor Juha Rouvinen and Dr. Lari Lehtio for reviewing my thesis and giving me valuable feedback and suggestions how to improve the thesis. All co-authors and collaborators in the research groups of Professor Sirpa Jalkanen, Professor Ferenc Fülöp, Professor Zbyszek Otwinowski and Biotie Therapies Corp. are acknowledged.

I would like to acknowledge the director, Professor Mark Johnson, and coordinator, Fredrik Karlsson, from the National Doctoral Programme in Informational and Structural Biology (ISB). I am glad to have been a part of the excellent ISB graduate school. During all meetings the scientific program holds high standard and the social events are a great source of inspiration. I would further like to express my gratitude towards my thesis committee members Dr. Lari Lehtio, Dr. Heli Elovaara and Dr. Jarno Käpylä.

I would also like to thank all past and present members of SBL for creating a nice work environment. I would especially like to thank Käthe Dahlstöm, Lenita Viitanen, Yvonne Nymalm-Rejström, Anna Brandt, Leonor Lopes de Carvalho, Jukka Lehtonen, Santeri Puranen, Tomi Airenne, Vimal Parkash, Bhanupratap
Singh Chouhan, Stina Sandberg and Outi Salo-Ahen. Käthe, I am glad that we crossed paths in SBL. You have been a tremendous support for me during these years and for that I am deeply grateful. You have been an excellent travel companion to courses and conferences. I have appreciated all of our scientific and non-scientific discussions. In addition, you have been a superb playmate for Edvin. Thank you Lenita, Yvonne and Anna for welcoming me into SBL. I appreciate your patience and all the practical help I got during my start in the lab. I would like to thank Vimal and Leonor for nice collaboration and co-authorship. I would like to thank Jukka for managing and solving every computer related problem that I have encountered during my stay at SBL. Santtu, Tomi, Bhanu, Stina and Outi, I appreciate all discussions we have had during the years.

I like to acknowledge the people in the former Biochemistry department. I want to thank Elsmarie Nyman, Pirkko Luoma, Eve Hed-Kattelus, Jussi Meriluoto and Juha-Pekka Sunila for all administrative and technical help I have received during the years at the department. I also want to extend my gratitude to my fellow graduate students inside and outside BioCity. Gloria, Daniela and Marika, it has been a pleasure to share this journey with you. I am proud not only to call you my colleagues but also my friends. I have appreciated all our discussions and I want to thank you for helping me in my work through your knowledge in doing research.

My dear friends, I am glad to have you all in my life. You encourage me in my work and in my life. Ninni, Heidi, Ida and Gunilla, we shared great moments during the masters studies, then you escaped BioCity but we stayed in touch and we have shared many great times during these years. Hopefully, there are many more to come. Pia, Carro, Leena, Tette and Sandra, I thank you for your friendship and support. You keep me aware about the world outside of science. I really enjoy our laughter and endless discussions just about anything and everything.

I want to thank my family for their endless support. My parents, Rose-Marie and Anders, are a continuous support and I want to thank them for all their help. My
brothers, Mikael and Roy, you are important to me and I am grateful that I can depend on you in times of need. At last, my greatest appreciation goes to my dear husband, Isak. Thank you for all our years together, for your love and support. Finally, I want to thank our son, Edvin, for keeping me on my toes and for all the love we share.

There were several institutions funding the work in this project. I gratefully acknowledge ISB, Stiftelsen för Åbo Akademi forskningsinstitut, Medicinska Understödföreningen Liv och Hälsa rf., Tor, Joe och Pentti Borgs minnesfond, K. Albin Johanssons stiftelse, Magnus Ehrnrooths stiftelse, Svenska Kulturfonden, Oskar Öflunds stiftelse, Harry Elvings legat, Turku Centre for Systems Biology and Åbo Akademi for financial support.

Eva Bligt-Lindén

Jeppo, November 2015
ABBREVIATIONS

2HP 2-hydrazinopyridine
bSAO Bovine serum amine oxidase
CAO Copper amine oxidase
CHO Chinese hamster ovary cell lines
DAO Diamine oxidase
FAD Flavin adenine dinucleotide
HEK Hamster embryonic kidney cells
hVAP-1 Human vascular adhesion protein-1
IC\textsubscript{50} Mean inhibitory concentration
JTT Jones-Taylor-Thornton substitution matrix
K\textsubscript{a} Association constant
K\textsubscript{d} Dissociation constant
LTQ Lysine tyrosylquinone
MAO Mono amine oxidase
ML Maximum likelihood method
NJ Neighbor-Joining method
PDB Protein data bank
PET Positron emission tomography
PO Polyamine oxidase
RAO Retina specific amine oxidase
Rmsd Root-mean-square deviation
SAO Serum amine oxidase
sVAP-1 Serum vascular adhesion protein-1
TPQ 2,4,5-trihydroxyphenylalanine quinone
VAP-1 Vascular adhesion protein-1
1. INTRODUCTION

There is an increasing need for anti-inflammatory therapy since a major part of contemporary human diseases in the Western countries is of an inflammatory nature. Vascular adhesion protein-1 (VAP-1) is a primary copper amine oxidase (CAO) and cell adhesion receptor, which is involved in several pathological conditions due to its proinflammatory effects and involvement in the leukocyte trafficking to sites of inflammation (Salmi & Jalkanen, 2014). Human VAP-1 has great potential as a drug target in acute and chronic inflammatory conditions like rheumatoid arthritis, psoriasis, atopic eczema, multiple sclerosis, diabetes, and respiratory diseases (Dunkel et al., 2011). There are two major strategies used to inhibit VAP-1; small molecular inhibitors and antibodies (Dunkel et al., 2011). The majority of the small molecular inhibitors are targeted to the active site cofactor of VAP-1. However, this irreversible mode of inhibition, where new enzyme synthesis is required to recover enzyme activity (Palfreyman et al., 1994), is an undesirable characteristic for a drug for human use. The ability to remove a drug and regain target activity within a short period of time is important and the active site channel of VAP-1 presents an advantageous alternative binding site for reversibly binding inhibitors in relation to the active site cofactor. In order to effectively develop inhibitors to target VAP-1, it is critical to understand the function of the protein on a cellular level, as well as, on a molecular level. In this study, a novel set of inhibitors and their binding mode to VAP-1 were evaluated with X-ray crystallography. Computational and experimental studies, together with evolutionary studies, further increase the knowledge about the protein function and the CAO family, which is of importance in the design of specific and potent inhibitors.
2. REVIEW OF THE LITERATURE

2.1 Amine oxidases

Amine oxidases are a family of proteins, which oxidize amines to their corresponding aldehydes in a reaction where hydrogen peroxide and ammonia are produced. The family consists of monoamine oxidases (MAO, EC 1.4.3.4), polyamine oxidases (PO, EC 1.5.3.17) and the copper amine oxidases (Floris, 2009). MAOs and POs have flavin adenine dinucleotide (FAD) as cofactor, while the copper amine oxidases can be further classified based on their quinone cofactor (Klinman, 1996), which is either a 2,4,5-trihydroxyphenylalanine quinone (TPQ) in copper-containing amine oxidases (CAOs; EC 1.4.3.21 primary amine oxidase and EC 1.4.2.22 diamine oxidase) or a lysine tyrosyl-quinone (LTQ) in lysyl oxidases (LOXs, EC. 1.4.3.13) (Klinman, 1996).

Two isoforms of MAO are present in humans: MAO A and MAO B. Both are located in the outer mitochondrial membrane of mammalian cells, and they catalyze the deamination of primary, secondary and tertiary amines. MAOs are linked to depression (Meyer et al., 2006) and they metabolize neurotransmitters such as serotonin, norepinephrine and dopamine (Shih et al., 1999). There are three isoforms of the POs and they are involved in the regulation of cellular growth by oxidizing polyamines such as spermine and spermidine (Seiler, 2004), while the CAOs oxidize primary amines. The members of the LOX family can convert the amino group of a lysine to an aldehyde and the product aldehyde can then react with a second lysine-derived aldehyde to form crosslinks important in the formation and stabilization of collagen and elastin (Lucero & Kagan, 2006).

2.2 CAOs

There are four genes, AOC1-4, coding for CAOs in mammals (Schwelberger, 2007). AOC1 encodes diamine oxidase (DAO) (EC 1.4.3.22), AOC2 encodes retina specific amine oxidase (RAO), AOC3 encodes vascular adhesion protein-1 (VAP-1) (EC 1.4.3.21), and AOC4 encodes a soluble paralog of VAP-1 called serum amine oxidase (SAO). All four genes have been identified in humans, pigs, horses, dogs, mice, rats, chimpanzees and macaques (Schwelberger, 2007). However, the AOC4 gene in human and the AOC2 gene in rat contains one internal stop codon each, resulting in truncated and nonfunctional proteins (Schwelberger, 2007; Zhang et al., 2003). Rodents are also missing an AOC4 gene.
product as they only have small fragments of the AOC4 gene (Schwelberger, 2007). The human AOC1 and AOC2/AOC3 share 38% sequence identity, AOC2 shares 65% identity with AOC3, while AOC3 and AOC4 share 90% identity. The interspecies sequence identity of mammalian CAOs (cow, horse, dog, chimpanzee, macaque, and human) is 80-95% (Schwelberger, 2010). The proteins are sometimes named AOC1, AOC2, AOC3 and AOC4, but in this thesis they are hereafter referred to as DAO, RAO, VAP-1 and SAO, respectively. The members of the CAO family all share a similar fold (Floris, 2009), which is discussed in chapter 2.4 where the structure of VAP-1 is presented in detail.

2.2.1 DAO (the AOC1 gene product)

DAO is mainly expressed in the kidney, placenta, intestine and seminal vesicles (Elmore et al., 2002). The protein is released from the cells in response to an external stimulus and it oxidizes both endogenous and exogenous histamine (Schwelberger, 2007). DAO differs from the rest of the CAOs as it oxidizes diamines compared to the other proteins that oxidize monoamines (Elmore et al., 2002). A decrease in DAO activity correlates with histamine intolerance (Maintz & Novak, 2007) and the balance between DAO and histamine is important in achieving an uncomplicated pregnancy (Maintz et al., 2008). The structure of human DAO (hDAO) was determined by McGrath and coworkers in 2009 (McGrath et al., 2009).

2.2.2 RAO (the AOC2 gene product)

RAO is the least known member of the CAOs. RAO was cloned from the retina of human in 1997 (Imamura et al., 1997). mRNA of RAO has been detected in the lung, brain, kidney, cartilage, tonsil and in the heart, but RAO activity has only been detected in the retina (Kaitaniemi et al., 2009). RAO oxidizes 2-phenylethylamine, tryptamine and p-tyramine in vitro (Kaitaniemi et al., 2009). The structure of RAO is not known but a structural model has been made based on the X-ray structure of human VAP-1 (Kaitaniemi et al., 2009). The overall fold of RAO is likely to be similar to the fold of hVAP-1 because of their high sequence identity (68%).

2.2.3 VAP-1 (the AOC3 gene product)

VAP-1 was cloned in 1998 (Smith et al., 1998) and it is expressed in adipocytes, vascular endothelial cells and in smooth muscle cells (Salmi & Jalkanen, 1992;
Salmi & Jalkanen, 2001; Zorzano et al., 2003). In endothelial cells VAP-1 is stored within intracellular granules, and upon inflammatory stimuli it is rapidly translocated to the cell surface (Jaakkola et al., 2000; Salmi et al., 1997; Vainio et al., 2005). Preferred substrates for VAP-1 are soluble amines like methylamine and aminoacetone, which are formed during intermediary metabolism (Lyles & Chalmers, 1992). VAP-1 is involved in several diseases and pathophysiological conditions, which will be discussed later in the text (Boomsma et al., 2003). VAP-1 is primarily a membrane-bound extracellular protein but it can also be proteolytically cleaved and exists in a soluble form in the blood (referred to as serum VAP-1 (sVAP-1)) (Abella et al., 2004; Kurkijarvi et al., 1998; Stolen et al., 2005). As humans are lacking SAO, it is the cleaved sVAP-1 that gives rise to the VAP-1 activity in the blood.

2.2.4 SAO (the AOC4 gene product)

Mature SAO results from the cleavage of a signal peptide, leaving the protein soluble in contrast to the membrane-bound RAO and VAP-1, which have an N-terminal transmembrane helix. In contrast to human, which is missing functional SAO, mammals such as cow, horse, pig and sheep have high levels of SAO activity in their blood (Boomsma et al., 2003; Schwelberger, 2007). Bovine SAO (bSAO) shows high affinity for physiological polyamines such as spermine, spermidine, long hydrophobic amines and benzylamine with hydrophobic substituents (Buffoni, 1966; Di Paolo et al., 2003; Hartmann & Klinman, 1991). The crystal structure of bSAO was determined by Lunelli and coworkers in 2005 (Lunelli et al., 2005).

2.3 The TPQ cofactor and the reaction mechanism of CAOs

The CAO cofactor TPQ is derived from a post-translationally modified tyrosine within the active site of the protein. Two possible conformations of the TPQ have been detected in the X-ray structures (Figure 1) (Parsons et al., 1995). It can adopt an on-copper conformation (Figure 1A), which is the inactive or resting conformation, and an active off-copper conformation (Figure 1B). In the inactive conformation, the O4 of TPQ ligates to a copper molecule in the active site and the O5 of TPQ points away from the substrate entry channel and the catalytic base (Asp 386 in VAP-1). In the active conformation, the TPQ is flipped 180° from the inactive conformation, the O2 forms a hydrogen bond to a water molecule that interacts with the copper, and the O5 is facing the substrate channel and the catalytic base.
Figure 1. Representation of the two possible TPQ conformations in CAOs. A) On-copper inactive conformation. B) Off-copper active conformation. The transparent TPQ is representing the alternative conformation in both pictures.

The reaction mechanism of CAOs (Figure 2) can be divided into two half-reactions: the reductive and the oxidative half-reactions. The reductive half-reaction is initiated when a substrate amine reacts with the O5 of the oxidized TPQ to form a covalent intermediate, a substrate Schiff base (Mure et al., 2002). A conserved, catalytic Asp residue abstracts the Ca-hydrogen from the substrate molecule yielding a product Schiff base (Wilmot et al., 1997). The product Schiff base is hydrolyzed and the aldehyde product is released, leaving a reduced amine group on TPQ (Su & Klinman, 1998; Wilmot et al., 1999). To reactivate the enzyme, the TPQ is oxidized by molecular oxygen in the oxidative half-reaction. TPQ returns to the resting form and H₂O₂ and NH⁴⁺ are released.
2.4 Structure of VAP-1

The structures of the CAO family members are all homodimers where each monomer is comprised of the three domains; D2, D3 and the catalytically D4 domain (Figure 3A). The crystal structure of human VAP-1 was solved in 2005 by two independent research groups (Airenne et al., 2005; Jakobsson et al., 2005). There were no large differences between the two structures except in the formation of the disulfide bridges, which is probably due to differences in the expression constructs. The structures were solved to 2.5-3.0 Å resolution. All mammalian structures determined to date are listed in Table 1.

The biologically active unit of VAP-1 is a dimer with a heart-shaped structure that is attached to the cell membrane via a transmembrane helix, which is not included in any of the available structures (Figure 3B). The active site of the protein is located deep in the D4 domain, which is the most conserved area. Each subunit of the protein has two long arm-like protrusions, arm I and arm II, which extend from one subunit to embrace the other subunit (Figure 3B). The important residues in the catalytic site are TPQ, the catalytically active base Asp386, and the three His520, His522 and His684 that coordinate the copper ion.
(Figure 1). Residues from the different domains form a rather long and narrow active site channel leading to the active site. Residues from D2 (85-88) and D3 (173-184, 206-212, 230-239) form one side of the cavity, while residues from arm I of the other subunit (444-450), together with residues from D4 (389, 393-397, 415-426, 467-469, 458-761, 762-673), form the other one.

VAP-1 has an RGD motif (residues 726-728), which is known to function in cell-cell and cell-matrix interactions in integrins (Ruoslahti & Pierschbacher, 1987). In VAP-1 the RGD motif is located on a solvent-exposed tip of a finger-like structure, which is ideal for interactions with a ligand (Airenne et al., 2005). Mutational studies have shown that deletion of the RGD motif diminish but do not abolish the leukocyte adhesion to VAP-1, while only slight variation of the motif (RDG -> RGA) does not cause any differences in leukocyte binding to VAP-1 transfecants (Salmi et al., 2000). The VAP-1 is a glycoprotein and it has been predicted to have six N-linked and three O-linked glycosylation sites (Figure 3B). All six of the N-linked glycosylation sites have been confirmed by X-ray structures and the three glycans on top of the protein are important for the cell adhesion (Airenne et al., 2005; Maula et al., 2005). Two of the glycosylation sites are located near the RDG-motif and the entrance to the active site channel. They might, therefore, control both the enzymatic activity and cell adhesion. The structure is stabilized by a number of intra- and interdomain disulfide bridges.
2.5 Adhesive function of VAP-1

In addition to the amine oxidase activity, VAP-1 has an adhesive function, as the protein participates in the adhesion of leukocytes to endothelium (Salmi & Jalkanen, 1992; Salmi et al., 1998). Salmi and coworkers discussed about a possible lymphocyte counter-receptor for VAP-1 already in 1992 (Salmi & Jalkanen, 1992). Subsequently, some peptides displaying a suitable free amine group were shown to bind VAP-1 (Yegutkin et al., 2004). Furthermore, Siglec-9 and Siglec-10 have been identified as leukocyte counter-receptors for VAP-1 through phage display screening (Aalto et al., 2011; Kivi et al., 2009). It has been suggested that a free amine group of an arginine in the C2- domain of the Siglecs can interact with the TPQ of VAP-1. Docking studies with peptides derived from
the predicted interaction region, containing Arg284 and Arg290 in Siglec-9 and Arg293 in Siglec-10, have shown that the peptides can fit in the VAP-1 active site cavity (Aalto et al., 2011; Kivi et al., 2009). However, the finding of Siglec-9 and Siglec-10 as counter receptors for VAP-1 does not exclude the possibility of other binding partners for VAP-1.

Table 1. Available mammalian CAOs structures. The structures from this study are marked with *.

<table>
<thead>
<tr>
<th>Structure</th>
<th>PDB</th>
<th>Resolution (Å)</th>
<th>Ligand</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAO</td>
<td>3HI7</td>
<td>1.80</td>
<td></td>
<td>(McGrath et al., 2009)</td>
</tr>
<tr>
<td>DAO</td>
<td>3HII</td>
<td>2.15</td>
<td>Penetamidine</td>
<td>(McGrath et al., 2009)</td>
</tr>
<tr>
<td>DAO</td>
<td>3HIG</td>
<td>2.09</td>
<td>Berenil</td>
<td>(McGrath et al., 2009)</td>
</tr>
<tr>
<td>DAO</td>
<td>3K5T</td>
<td>2.11</td>
<td></td>
<td>(McGrath et al., 2010a)</td>
</tr>
<tr>
<td>DAO</td>
<td>3MPH</td>
<td>2.05</td>
<td>Aminoguanidine</td>
<td>(McGrath et al., 2010b)</td>
</tr>
<tr>
<td>VAP-1</td>
<td>1PU4</td>
<td>3.20</td>
<td></td>
<td>(Airenne et al., 2005)</td>
</tr>
<tr>
<td>VAP-1</td>
<td>1US1</td>
<td>2.90</td>
<td></td>
<td>(Airenne et al., 2005)</td>
</tr>
<tr>
<td>VAP-1</td>
<td>2C10</td>
<td>2.50</td>
<td></td>
<td>(Jakobsson et al., 2005)</td>
</tr>
<tr>
<td>VAP-1</td>
<td>2C11</td>
<td>2.90</td>
<td>2HP</td>
<td>(Jakobsson et al., 2005)</td>
</tr>
<tr>
<td>VAP-1</td>
<td>2Y73</td>
<td>2.60</td>
<td>Imidazole, on-copper</td>
<td>(Elavaara et al., 2011)*</td>
</tr>
<tr>
<td>VAP-1</td>
<td>2Y74</td>
<td>2.95</td>
<td>Imidazole, off-copper</td>
<td>(Elavaara et al., 2011)*</td>
</tr>
<tr>
<td>VAP-1</td>
<td>3ALA</td>
<td>2.90</td>
<td></td>
<td>(Ernberg et al., 2010)</td>
</tr>
<tr>
<td>VAP-1</td>
<td>4BTW</td>
<td>2.80</td>
<td>Inhibitor 6</td>
<td>(Bliigt-Linden et al., 2013)*</td>
</tr>
<tr>
<td>VAP-1</td>
<td>4BTX</td>
<td>2.78</td>
<td>Inhibitor 7</td>
<td>(Bliigt-Linden et al., 2013)*</td>
</tr>
<tr>
<td>VAP-1</td>
<td>4BTY</td>
<td>3.10</td>
<td>Inhibitor 13</td>
<td>(Bliigt-Linden et al., 2013)*</td>
</tr>
<tr>
<td>bSAO</td>
<td>1TU5</td>
<td>2.37</td>
<td></td>
<td>(Lunelli et al., 2005)</td>
</tr>
<tr>
<td>bSAO</td>
<td>2PNC</td>
<td>2.40</td>
<td>Clonidine</td>
<td>(Holt et al., 2008)</td>
</tr>
</tbody>
</table>
2.6 Extravasation of leukocytes to inflamed tissue

For the immune defense to function properly, leukocyte trafficking between the blood, the lymphoid organs and affected tissues is essential. VAP-1 is one of many proteins controlling and participating in the multistep extravasation cascade when leukocytes transmigrate from the blood into tissues (Salmi & Jalkanen, 1992; Salmi & Jalkanen, 2014). In vitro binding assays and intraviral microscopy studies have shown that VAP-1 is involved in the rolling, firm adhesion and the transmigration step of the cascade (Figure 4) (Koskinen et al., 2004; Lalor et al., 2002; Salmi et al., 2001; Salmi & Jalkanen, 2001; Stolen et al., 2005; Tohka et al, 2001). According to the current hypothesis, the leukocyte first interacts with VAP-1 through epitopes on Siglec-9 and -10 (Aalto et al., 2011; Kivi et al., 2009) and then the leukocyte slows down, tethers and rolls along the vessel wall. When it arrests, a covalent but transient Schiff base is formed between Siglec and VAP-1. If there are appropriate activation signals, the bound leukocyte transmigrates through the vessel wall and continues toward chemotactic signals within the tissue. The adhesive and enzymatic functions of hVAP-1 are connected since adhesion is reduced when the enzymatic activity is inhibited (Koskinen et al., 2004; Salmi & Jalkanen, 2001).

![Blood flow diagram](image)

Figure 4. VAP-1 is involved in the rolling, firm adhesion and transmigration step of the extravasation cascade of leukocytes to sites of inflammation.

2.7 VAP-1 in inflammatory diseases

In addition to the direct manner of bringing the leukocyte and endothelial cell in contact with each other during the extravasation of leukocytes to sites of inflammation, VAP-1 can also affect the immune defense in an indirect manner.
by altering the environment in a proinflammatory direction via signaling effects. Both the product aldehyde and the side products, hydrogen peroxide and ammonium can induce expression of other endothelial adhesion molecules and chemotactic substances, as well as activation of transcription factors, which further accelerate the inflammation (Jalkanen et al., 2007; Lalor et al., 2007; Liaskou et al., 2011; Salmi et al., 2001). Therefore, VAP-1 activity increases the leukocyte recruitment to the vascular wall, and induces vascular dysfunction by causing direct oxidative damage and also by increasing amyloid aggregation and blood pressure (Jalkanen & Salmi, 2008). The oxidation of lipids through VAP-1–generated hydrogen peroxide can also contribute to vascular damage (Chen et al., 2006; Gokturk et al., 2003).

Inflammation is involved in a wide variety of diseases in the cardiovascular, respiratory, gastrointestinal, musculoskeletal and nervous system (Roivainen et al., 2012) and VAP-1 has been connected to several pathological conditions and diseases. sVAP-1 levels are increased in both insulin-dependent (type 1) and non-insulin-dependent (type 2) diabetes (Garpenstrand et al., 1999; Li et al., 2009a; Salmi et al., 2002). Elevated levels of sVAP-1 have been seen in atherosclerosis (Li et al., 2009b) and VAP-1 activity is connected to preclinical atherosclerosis, affecting the intima-media thickness and carotid plaques (Aalto et al., 2012).

VAP-1 has also been connected to chronic kidney disease (Lin et al., 2008), inflammatory liver diseases (Kurkijarvi et al., 1998; Lalor et al., 2007) and congestive heart failure (Boomsma et al., 1997). It has been shown that VAP-1 is important in the pathogenesis of arthritis (Marttila-Ichihara et al., 2006) and elevated VAP-1 levels have been detected in patients with systemic sclerosis (Yanaba et al., 2013), multiple sclerosis (Airas et al., 2006) and psoriasis (Madej et al., 2007). VAP-1 appears to play an important role in the development of liver fibrosis (Weston et al., 2015) and in allergic inflammatory responses of the airways (Dunkel et al., 2014). It has been connected to acute ocular inflammation, ocular angiogenesis and pathophysiology (Noda et al., 2008a; Noda et al., 2008b). Moreover, VAP-1 is involved in nonclassical inflammatory diseases like cancer. VAP-1 gene amplification has been detected in the genome of gastric cancer patients (Varis et al., 2002) and VAP-1 activity is upregulated in colorectal cancer tissues (Li et al., 2014). Specimens from head, neck, liver and melanoma tumors also show increased VAP-1 expression (Forster-Horvath et al., 2004; Irljala et al, 2001; Yoong et al., 1998).
In vitro and in vivo studies have clarified several aspects of the VAP-1 function. In VAP-1 deficient mice (knock out) the cell migration during inflammation is decreased (Stolen et al., 2005) and tumors grow more slowly (Marttila-Ichihara et al., 2009). Overexpression of VAP-1 at the cell surface of endothelial cells leads to increased binding of lymphocytes affecting the transmigration cascade. Studies have also shown that the oxidase activity of the protein is of importance in neoangiogenesis, cell recruitment, tumor growth and inflammation (Marttila-Ichihara et al., 2009; Noonan et al., 2013). The VAP-1 activity is dependent on the oxidase activity and, moreover, the oxidase activity is entirely dependent on the TPQ, as mutagenesis of this residue abolishes all catalytic activity of VAP-1 (Koskinen et al., 2007; Noonan et al., 2013). To summarize, these data show that the enzymatic activity of VAP-1 is crucial in leukocyte migration (Salmi & Jalkanen, 2014).

2.8 VAP-1 as drug target

As inflammation is involved in a wide variety of diseases involving for example the cardiovascular, respiratory, gastrointestinal, and nervous system, there is a great need for anti-inflammatory therapy. VAP-1 and its involvement in the leukocyte trafficking to sites of inflammation make it an attractive drug target (Smith & Vainio, 2007). The impact of VAP-1 immunotherapy is much needed as chronic inflammatory diseases increase in Western industrialized countries due to the socioeconomically standard and aging population (Thorburn et al., 2014; MacNee et al., 2014).

The dual function of VAP-1 gives it advantages as drug target over other adhesion receptors, since both the adhesive and enzymatic activity can be inhibited (Salmi & Jalkanen, 2005). The catalytic center of an enzyme presents a good starting point for rational drug design as analogues of known substrates and inhibitors can be designed and developed. Available crystal structures further aids in the planning of novel inhibitors. The fact that the adhesive function of VAP-1 is inhibited by small molecular inhibitors, which can be administered orally, is a clear benefit over drugs that need to be injected intravenously or subcutaneously (Jalkanen & Salmi, 2008).

In order to block the function of VAP-1, it is critical to understand the function of the protein at the molecular level (Finney et al., 2014). Both small molecular
inhibitors and antibodies have proven successful and effective in inhibiting leukocyte-endothelial cell interactions in several disease models (Koskinen et al., 2004; Lalor et al., 2002). Alleviation of disease state and leukocyte trafficking has been seen in the following models: liver transplantation (Martelius et al., 2004; Martelius et al., 2008), liver fibrosis (Weston et al., 2015), arthritis (Marttila-Ichihara et al., 2006), lung inflammation (Foot et al., 2012; Foot et al., 2013; O’Rourke et al., 2008) and in encephalomyelitis in mice which shares characteristics with human multiple sclerosis (O’Rourke et al., 2007).

Recently, VAP-1 has also emerged as a target for in vivo imaging of inflammation (Aalto et al., 2011; Li et al., 2013; Luo et al., 2013; Roivainen et al., 2012). Utilizing the detection of inflammation-induced luminal VAP-1 as an imaging target could have major clinical impact, and the method can be used as a diagnostic tool for the detection and characterization of inflammatory diseases. Positron emission tomography (PET) imaging with a $^{68}$Ga-labelled peptide of Siglec-9 has been shown to detect VAP-1 in vasculature at sites of inflammation and cancer (Aalto et al., 2011).

2.9.1 Anti-VAP-1 antibodies

It has been shown both in vitro and in vivo that anti-VAP-1 antibodies can block the adhesive function of VAP-1 to promote leukocyte transmigration in humans and, thus, reduce the migration of leukocytes. It has also been shown that the antibody-mediated inhibition did not lead to any side effects in the immune system (Kirton et al., 2005, Koskinen et al., 2007). Monoclonal antibodies bind to VAP-1 in an area, which does not inhibit the oxidase activity of the protein (Koskinen et al., 2004; Bonder et al., 2005; Merinen et al., 2005). Function-blocking antibodies reduce the number of infiltrating leukocytes in acute and chronic inflammatory models including dermatitis (Vainio et al., 2005), peritonitis (Merinen et al., 2005), liver rejection, and hepatitis (Bonder et al., 2005; Martelius et al., 2004). Humanized and function-blocking anti-VAP-1 antibodies have also been produced (Autio et al., 2013; Kirton et al., 2005). BTT-1023 has shown efficacy and safety in clinical studies in arthritis and psoriasis patients (Autio et al., 2013). It has also shown efficacy in a range of preclinical models of inflammatory diseases, including chronic obstructive pulmonary disease, certain neurological conditions, and certain niche liver inflammatory fibrotic diseases. Currently, BTT-1023 is undergoing phase 2 clinical trials (Autio et al., 2013).
2.9.2 Small molecular inhibitors

CAO activity can be inhibited by carbonyl reactive groups such as semicarbazide (Figure 6A) and hydrazines (Lyles, 1996). The hydrazines were initially designed to inhibit MAO A and MAO B, but they also inhibit CAOs, such as VAP-1 and DAO (Lizcano et al., 1996). Therefore, they are not specific and they bind irreversibly, which is not a desirable feature. Thereafter, different types of small molecules have been developed that can be grouped into two main classes: irreversible mechanism based inhibitors (Figure 5A, B, C D&E) and noncovalent/reversibly binding inhibitors (Figure 5F&G) (McDonald et al., 2007; Dunkel et al., 2011). The irreversible inhibitors are either based on allylamines (Figure 5B&C) or hydrazines (Figure 5D&E). Other molecules known to inhibit VAP-1 are: amino acid derivatives, benzamides, oxime-based SSAO inhibitors, aminoglycoside antibiotics, vitamin B1 derivatives, and peptides (Dunkel et al., 2008; Dunkel et al., 2011). More recently developed inhibitors, such as, ELP 12, LJP1207, PXS-4861A, BTT-2052 and LJP1586 have proven specificity and potency for VAP-1 (Figure 5) (Bonaiuto et al., 2012; Wang et al., 2006; Foot et al., 2013; Marttila-Ichihara et al., 2006; O’Rourke et al., 2008).
2.9.3 CAO structures in complex with inhibitors

The crystal structure of human VAP-1 in complex with the irreversible inhibitor 2-hydrazinopyridine (2HP; PDB code 2C11) shows a covalent bond between the C5 atom of TPQ and the inhibitor, which forms a substrate Schiff base mimic (Figure S5E of Supporting Information in publication 1) (Jakobsson et al., 2005). As 2HP contains nitrogen instead of a carbon at the C1 position, the covalent complex formed with the inhibitor cannot be deprotonated and, thus, accumulates in the crystal. Therefore, the hydrazine compounds are suicide inhibitors and once they react with TPQ, they cannot be released from the catalytic site.

bSAO and DAO have both been crystallized with non-covalently bound inhibitors. Holt and coworkers solved the complex structure of bSAO and clonidine (Figure S5C of Supporting Information in publication 1) (PDB code 2PNC) (Holt et al., 2008). The inhibitor-bound structure does not show any major differences compared to the native structure, except that Asn469 has
rotated 180° in the active site channel to allow binding of clonidine. The aromatic ring of clonidine \( \pi \)-stacks with TPQ and Tyr 472, while two nitrogen atoms of clonidine hydrogen bond to Tyr383 and the catalytic base Asp385. The catalytic base, Asp386 in DAO is also hydrogen bonding the non-covalently bound inhibitors berenil and pentamidine in the complex structures of DAO (Figure 3 in publication II) (PDB codes 3HIG and 3HII) (McGrath et al., 2009). Asp186 in the active site channel is involved in interaction with pentamidine and both inhibitors \( \pi \)-stack with Trp376 and Tyr371. Berenil binds in an extended conformation, while pentamidine adopts a bent horseshoe conformation. Based on the analysis of previous CAO inhibitors, and the binding mode of irreversible VAP-1 inhibitors, it would be advantageous to develop reversible VAP-1 inhibitors.
3. AIMS OF THE STUDY

The overall goal of this study was to understand the structural and functional properties of the active site in CAOs, especially in VAP-1. As VAP-1 is a known drug target in inflammatory diseases, the primary aim was to study the VAP-1-ligand interaction at atomic level. New insight in the ligand interactions of CAOs and VAP-1 is valuable in the drug development against these targets.

The specific aims were as follows:

I. To analyze the structural properties of VAP-1 with X-ray crystallography and to study the active sites of VAP-1 and RAO to understand their differences in substrate preference (Publication I).

II. To evaluate the molecular interaction between VAP-1 and potent inhibitors targeted to the novel binding site of VAP-1 discovered in Publication I (Publication II).

III. To identify the underlying reasons for species specific binding of ligands in VAP-1 (Publication III).

IV. To study the evolutionary relationship of mammalian CAO in detail, to identify and classify new and poorly characterized CAOs and derive general rules for substrate specificity in this class of enzymes (Publication IV).
4. MATERIAL AND METHODS

The material and methods that were used in this study are described in full detail in the respective publication (I-IV). The brief descriptions below are presented to give an overview.

4.1 Crystallography

4.1.1 Extraction of VAP-1 for crystallization (I, II)

The soluble form of VAP-1 was extracted and purified from human serum by Biotie Therapies Corp. The sample was dialyzed against 10 mM potassium phosphate (pH 7.2) and prior to crystallization the protein was concentrated in Eppendorf concentrators by centrifugation at 12000 rpm at 4° to approximately 1.0 mg/ml. The protein was stored at 4°.

4.1.2 Crystallization and diffraction data collection (I, II)

The protein was crystallized using the hanging drop vapor diffusion technique at room temperature. The imidazole complexes were crystallized by mixing the protein with a well solution of 0.7 M Na/K tartrate, 100 mM imidazole (pH 7.4), and 200 mM NaCl (Publication I). For co-crystallization of the inhibitor complexes VAP-1 was incubated with the inhibitors for 1 h at 37° in a 1:10 molar ratio prior to crystallization setup. The crystals grew in a crystallization condition containing protein and 0.7 Na/K tartrate, 0.2 M NaCl, 0.1 M Hepes, pH 7.4-7.6, and 200 mM NaCl (Publication II). Before data collection the crystals were dipped in a cryoprotectant of 0.6–0.8 M Na/K tartrate, 0.2 M NaCl, 0.1 M Hepes, pH 7.6, 1.3–2 M Na formate and 100 mM imidazole (Publication I) or 0.05 mM of inhibitor (Publication II), and then cryocooled in liquid nitrogen. Diffraction data collection was carried out at MAX-lab (Lund, Sweden) (Publication I) and European Synchrotron Radiation Facility (Grenoble, France) (Publication II).

4.1.3 Data processing, structure solution and refinement (I, II)

XDS (Publication I) (Kabsch, 2010) and HKL3000 (Publication II) (Otwinowski & Minor, 1997) were used for processing of the diffraction data. All structures belonged to the P6_22 space group. The structures were solved with molecular
replacement using the CCP4i program suite (Dodson et al., 1997) with the dimer of human VAP-1 structure (PDB code 1US1) (Airenne et al., 2005) as the search model. Inhibitor crystals showed significant anisotropy. During data processing, due to very weak diffraction and a low signal-to-noise ratio, the threshold for peak search was changed in order for the autoindexing to work for the VAP-1-13-complex in publication II. Computational corrections for absorption in a crystal, corrections for minor misalignment of the goniostat, together with corrections for anisotropic diffraction, were all implied during data processing of the VAP-1-inhibitor structures (Publication II) (Borek et al., 2003; Borek et al., 2010; Borek et al., 2013; Dodson et al., 1997). Refinement was done with REFMAC5 (Publication I & II) (Murshudov et al., 1997) and PHENIX (Publication I) (Adams et al., 2010). The structures were rebuilt in COOT (Emsley & Cowtan, 2004) and assessed with Molprobity (Davis et al., 2007). Pymol (DeLano, 2008) was used to analyze and visualize the structures and to make figures.

4.2 Activity measurements of VAP-1 activity

The activity measurements were done by collaborators in Sirpa Jalkanen’s research group or BioTie Therapies Corp. The inhibitors in publication II were designed and synthesized by BioTie Therapies Corp. and Ferenc Fülöp’s research group.

4.2.1 Protein expression for activity measurements (I, II)

The recombinant VAP-1 used in the VAP-1 activity and inhibition measurements was expressed in either Chinese hamster ovary cell lines for hVAP-1 (CHO-VAP-1), which have previously been reported (Smith et al., 1998), or Hamster embryonic kidney (HEK) 293 EBNA cells (Publication I & II). The CHO cells are stably transfected with a full-length human VAP-1 cDNA. The corresponding recombinant mouse VAP-1 and cynomolgus monkey VAP-1 proteins were also obtained from CHO cells (Publication II). Rat MAO was prepared from rat liver (Nurminen et al., 2011) and purified human MAO A and MAO B were purchased from Sigma-Aldrich (Publication II).

4.2.2 Inhibition with imidazole and inhibitors (I, II)

The role of imidazole on VAP-1 activity was determined radiochemically with CHO-VAP-1 lysate and labeled benzylamine based on the method of Fowler and
Tipton (Publication I) (Fowler and Tipton, 1981). The *in vitro* inhibition of VAP-1 activity with inhibitors was tested with a coupled colorimetric method where the measured increase in absorbance during the experiment reflects the VAP-1 activity (Publication II) (Holt et al., 1997; Nurminen et al., 2010; Nurminen et al., 2011). MAO activity and inhibition thereof was tested in the same way, with exception of the substrate (tyramine for MAO and benzylamine for VAP-1). The binding kinetics of inhibitors 6 and 7 to VAP-1 were analyzed in a binding assay with a Biacore T100 instrument where recombinant purified VAP-1 was amine coupled to a CM5 sensor chip (Publication II).

### 4.2.3 Enzyme activity assays for VAP-1 mutants (I)

The activity of VAP-1 mutants was determined by correlating it to the changes in their H$_2$O$_2$ production with and without semicarbazide inhibition (Publication I). The H$_2$O$_2$ production was quantified using an Amplex Red-labeled phenoxazine reagent and fluoropolarimeter (Salmi et al., 2001).

### 4.3 Modeling (II, III, IV)

All sequences were retrieved from the UniProt Knowledgebase (The UniProt Consortium, 2015): mouse VAP-1 (O70423), rat VAP-1 (O08590), monkey VAP-1 (G7PUW6) and human RAO (O75106). hVAP-1 (PDB code 2Y74) and hVAP-1 in complex with inhibitor 13 (PDB code 4BTW) were used as template structures in publications II and III. hVAP-1 (PDB code 4BTX) was used as template to model RAO in publication IV. BODIL and MALIGN were used for sequence alignment (Lehtonen et al., 2004) and MODELLER (Sali & Blundell, 1993) was used to generate the homology models. For each protein, ten models were generated, and in each case, the model with the lowest energy based on the objective function was chosen for further analysis. Surflex (Laskowski, 1995) and Mask were used to calculate the active site cavities and to extract the residues lining the binding site.

### 4.4 Phylogenetic studies (IV)

The phylogenetic study was done by my co-author, PhD student Leonor Lopes de Carvalho. Sequences for DAO (UniProtKB code: P19801), RAO (O75106), VAP-1 (Q16853) and bSAO (Q9T0K6) proteins, were obtained from the UniProt knowledgebase (Uniprot consortium 2015). To identify potential CAOs several BLAST searches (Altschul et al., 1990) were done using hDAO, hRAO,
hVAP-1 and bSAO as query against mammalian genomes with the protein blast program provided by the National Center for Biotechnology Information (NCBI, http://blast.ncbi.nlm.nih.gov). The phylogenetic reconstruction was performed using MEGA5 (Tamura et al., 2011) and calculated with Neighbor-Joining (NJ) (Saitou & Nei, 1987) and Maximum Likelihood methods (ML). The Jones-Taylor-Thornton (JTT) (Jones et al., 1992) substitution matrix was used to generate the trees. The topologies of the trees were inferred with bootstrap consensus trees using 500 replications (Felsenstein, 1985). Multivariate analysis (PCA, MS Johnson) was also done based on the phylogenetic distance data in MEGA5.
5. RESULTS

5.1 Serum VAP-1 in complex with imidazole (I)

5.1.1 Serum VAP-1 crystal structure (I)

We determined the first three dimensional structure of cleaved soluble serum VAP-1 with X-ray crystallography. Two crystal structures of hVAP-1 were refined to 2.60 and 2.95 Å with final Rfactors of 17.5% (Rfree = 21.3%) and 17.9% (Rfree = 21.4%) (Table 1 in I). Two imidazole molecules originating from the crystallization buffer were bound in both hVAP-1 structures, one molecule (Imid1) at TPQ and another (Imid2) in the active site channel. Overall, the structures are similar with a root-mean-square deviation (rmsd) of 0.12 Å for 1200 Ca atoms, but TPQ in the active site is interacting with Imid1 in different ways (Figure 6). In the 2.60 Å structure the TPQ in inactive on-copper conformation hydrogen bonds to Imid1 (Figure 6A), while in the 2.95 Å structure the TPQ in active off-copper conformation is covalently bound to Imid1 (Figure 6B). Asp386 also forms a hydrogen bond with Imid1 in both structures.

![Figure 6. TPQ conformations of the sVAP-1 structures. A) In the on-copper inactive conformation, imidazole (Imid1) is hydrogen bonded to TPQ (PDB code 2Y73). B) In the off-copper active conformation, imidazole (Imid1) is covalently bonded to TPQ (PDB code 2Y74). The omit maps for TPQ and Imid1 are contoured at σ level 1.0. (Publication I, Figure 1)](image)

5.1.2 Identification of a secondary imidazole binding site (I)

A novel secondary imidazole binding site was determined as an imidazole molecule (Imid2) could be modeled in the active site channel (Figure 7). The Imid2 forms a hydrogen bond to Tyr394 and a water-mediated contact with the main chain nitrogen of Thr212 in all chains of both structures. The OH group of Thr212 in chain B of the on-copper structure is also making a water-mediated
hydrogen bond to Imid2 (Figure 7A), while the Thr212 side chain has flipped and participates in a hydrogen bonding network with Arg216 and Tyr176 in both chains of the off-copper structure and in chain A of the on-copper structure (Figure 7B). Additionally, Leu469 and Tyr176 form hydrophobic contacts with Imid2.

Figure 7. The novel secondary imidazole binding site in the active site channel of hVAP-1. A) Thr212 side chain makes a water-mediated interaction to the imidazole (Imid 2) bound in the active site channel (PDB code 2Y73). B) Thr212 side chain is hydrogen bonded to Arg216 in the off-copper structure (PDB code 2Y74). Tyr394 is hydrogen bonded to Imid2 in both structures. The omit maps for Imid1 and Imid2 are contoured at σ level 1.0. (Publication I, Figure 2)

5.1.3 Imidazole inhibits VAP-1 enzymatic activity (I)

The effect of imidazole on VAP-1 activity was tested in an assay by monitoring the formation of radioactive benzylaldehyde from 14C-labeled benzylamine. Imidazole clearly inhibits the hVAP-1 enzymatic activity with an IC₅₀ of 1.28-8.6 mM (95% confidence interval) (Figure 4 in I). A 100 mM imidazole concentration, which corresponds to the crystallization setup, inhibits 93% of the hVAP-1 activity.

5.2 Pyridazinone inhibitors of VAP-1 (II)

5.2.1 Potent pyridazinone inhibitors of VAP-1 (II)

To target the secondary imidazole binding site in the active site channel, a novel set of pyridazinone inhibitors was designed and synthesized (Figure 8) (Scheme 1 and 2 in II). In vitro activity testing of inhibitors 6, 7 and 13 with recombinant VAP-1 show that the compounds are very potent against human VAP-1 enzyme activity, having IC₅₀ values from 290 to 20 nM (Table 1 in I). Inhibitor 13 is the
most potent human VAP-1 inhibitor with an IC$_{50}$ value of 20 nM, while inhibitor 6 has an IC$_{50}$ value of 71 nM and inhibitor 7 has the lowest activity with an IC$_{50}$ value of 290 nM. The biacore surface plasmon resonance analysis demonstrates a high affinity binding (K$_D$ = 0.17 × 10$^{-6}$ M for 6 and K$_D$ = 0.20 × 10$^{-6}$ M for 7) with very fast association kinetics ($k_a = 1.00 \times 10^{-6}$ M$^{-1}$ s$^{-1}$ for 6 and $k_a = 1.88 \times 10^{-6}$ M$^{-1}$ s$^{-1}$ for 7) and moderate dissociation kinetics ($k_d = 0.17 \times 10^{-6}$ s$^{-1}$ for 6 and $k_d = 0.38 \times 10^{-6}$ for 7) when hVAP-1 is immobilized on a chip. The kinetic studies confirm that the inhibitors bind reversible to VAP-1.

![Chemical structures](image)

Figure 8. The structures of the pyridazinone inhibitors 6, 7 and 13.

5.2.2 The inhibitors present a novel binding mode to VAP-1 (II)

To study the binding mode of inhibitors 6, 7 and 13 at a molecular level, they were co-crystallized with hVAP-1 and their crystal structures were determined. The structures were refined to 2.80 Å, 2.78 Å, and 3.10 Å resolution, with R-factors of 20.5% (Rfree of 26.0%), 17.4% (Rfree of 23.6%), and 18.5% (Rfree of 25.0%), respectively (Table 2 in publication II). All crystals showed significant anisotropy, and correction for this was especially important for successful data processing and quality of the final electron density maps. Despite the anisotropy, the electron density was good throughout the structures (Supporting Information Figure 2A&B in II).

The X-ray structures reveal that inhibitors 6, 7, and 13 bind in the active site channel (Figure 9A-E), close to the previously determined secondary imidazole
binding site (Figure 9F). The TPQ is in active off-copper conformation in all the chains of the complex structures and the structures are similar with an rmsd of 0.28-0.40 Å after superimposition. All three inhibitors bind noncovalently to hVAP-1 through hydrogen bonds, π-stacking, and hydrophobic interactions. Due to similar scaffold, the inhibitors show a similar reversible binding mode with only minor differences (Figure 9). Tyr394, Asp180, and Thr212 form hydrogen bonds to all the inhibitors. Tyr176 π-stacks to the pyridazinone of all inhibitors and Phe389 makes a T-shaped π-stacking with the phenyl ring of inhibitors 6 and 7, as well as a Cl–π interaction with inhibitor 13. Tyr448 on arm I originating from the other monomer make a hydrogen bond with all inhibitors and Phe173, Leu177, Leu468, and Leu469 interact hydrophobically with the inhibitors. The side chain of Thr212 in all B chains make hydrogen bonds through a water molecule to the inhibitors (Figure 9D), while in all A chains the side chain is flipped 180° and does not interact with the inhibitors (Figure 9B,C,E). Similar to the interactions of the Thr212 side chain in the on-copper imidazole structure, Thr212 in all A chains of the VAP-1-inhibitor complex structures forms a hydrogen bond to Arg216. The secondary imidazole binding site and the inhibitor binding site are overlapping (Figure 9F). However, there are differences as the imidazole moiety of the inhibitors is not exactly in the same position as the Imid2 in the sVAP-1 structures. Imid2 and the inhibitors are binding in close proximity of each other in the channel and Tyr394 interact with hydrogen bonds to both Imid2 in the sVAP-1 structures and all three VAP-1 inhibitor structures (Figure 9F).
Figure 9. Molecular binding mode for inhibitors 6, 7, and 13 in hVAP-1. A) Overall view of the VAP-1 inhibitor complexes. The inhibitors bind in the active site channel and block the access to the TPQ. B) Binding mode for inhibitor 6 (PDB code 4BTY). C) Binding mode for inhibitor 7 (PDB code 4BTX). Thr212 makes hydrogen bond to Arg216. D) Binding mode of 7 in chain B, where Thr212 is involved in a water-mediated hydrogen bond to the inhibitor. E) Binding mode for inhibitor 13 (PDB code 4BTW). F) Comparison of imidazole (Imid2) bound in the secondary imidazole binding site and the binding site for inhibitor 13. The σ-weighted 2F₀ – F₁ electron density maps are contoured at 1.5 σ in C–E and at 1.0 σ in B. (Adapted from Publication II, Figure 2.)

5.2.3 The inhibitors show specificity for VAP-1 over other CAOs (II)

In addition to the high potency for the human VAP-1, the pyridazinone inhibitors have excellent specificity for VAP-1 over other CAOs like MAO and DAO (Table 1 in II). Only 3-18% of total rat MAO activity was inhibited at 100
μM concentration and inhibition data for inhibitors 6 and 13 show similar results for human MAO A and human MAO B with 20 μM inhibitor concentration. Inhibitor 6 and 7 inhibits 40% and 30% of DAO activity at 100 μM concentration, respectively, while inhibitor 13 inhibits 36% of DAO activity at 50 μM concentration.

5.2.4 The inhibitors are weak inhibitors of mouse VAP-1 activity (II)

Even though inhibitors 6, 7, and 13 are potent hVAP-1 inhibitors they are surprisingly weak inhibitors of mouse VAP-1 activity (Figure 10). Inhibitor 6 and inhibitor 13 show a similar effect with 24% and 23% inhibition of the mouse VAP-1 activity, while inhibitor 7 shows the lowest inhibitory effect with a 10% inhibition of the mouse VAP-1 activity. Enzymes of rodent species such as rat, guinea pig and hamster also show lack of VAP-1 inhibition by the pyridazinone inhibitors. However, the potency against the enzyme of another primate, cynomolgus monkey, is very similar to human VAP-1 for all three inhibitors with IC₅₀ values of 26-250 nM (Table 1 in II).

![Figure 10. hVAP-1 and mouse VAP-1 activity inhibition by inhibitors 6, 7 and 13. The inhibitors are very potent against hVAP-1 but do not inhibit mouse VAP-1 well.](Publication II, Figure 1)

5.3 Structural comparison of rodent and primate VAP-1 active site (II, III)

5.3.1 Differences affecting the architecture of the active site (III)

To identify differences in primate and rodent VAP-1 active site, which could explain the species specific ligand binding seen in publication II, sequence alignments and homology models of the proteins were generated. Homology models of mouse, rat, and cynomolgus monkey VAP-1 were made based on the
hVAP-1 crystal structure. The overall fold of the proteins is very similar due to high sequence identities, 83% for mouse, 82% for rat and 96% for monkey compared to human VAP-1. The sequence identity between the mouse and rat VAP-1 sequence is very high, 93%. Residues lining the active site cavity were derived with the program Mask, and the residues that differ among the 4 species are listed in Table 2. There are no differences in the primary binding site close to TPQ. However, around the secondary imidazole binding site and where the pyridazinone inhibitors bind, there are several substitutions that affect the architecture of the active site channel.

Looking at the shape of the active site cavities, there are clear differences between primate and rodent VAP-1 (Figure 11A&B). The cavity is narrower in the rodents because of the Leu447\textsuperscript{primate}/Phe\textsuperscript{rodent} substitution, as the Phe is larger and occupies more space than the Leu in the primate protein. This residue is actually placed on the tip of Arm I coming from the other monomer of the protein. Three substitutions, Phe173\textsuperscript{primate}/Thr\textsuperscript{rat}/Asp\textsuperscript{mouse}, Leu177\textsuperscript{primate}/Gln\textsuperscript{rodent} and Asp180\textsuperscript{primate}/Gln\textsuperscript{rat}/Glu\textsuperscript{mouse} are located on α-helix5 of the D3 domain at the entrance to the active site channel. Furthermore, Thr210\textsuperscript{primate}/Lys\textsuperscript{rat} substitution in rat VAP-1 affects the shape of the active site. There is, however, only one single difference between the human and monkey VAP-1, Thr212\textsuperscript{human}/Asn\textsuperscript{monkey}.

5.3.2 Key substitutions causing species specific binding (II)

Even though the pyridazinone inhibitors are potent against human VAP-1, they are only weak inhibitors of mouse VAP-1, with a 10-24% inhibition of mouse VAP-1 activity. A homology model of mouse VAP-1 in complex with inhibitor 13 (done based on the hVAP-1-13-complex structure) shows the key substitutions in the active site channel (Figure 11C). Inhibitor 13 is bound in the channel exactly where the Arm I from the other monomer reach into the active site. The Leu477\textsuperscript{human}/Phe\textsuperscript{mouse} substitution will, therefore, affect the inhibitor binding. The Phe173\textsuperscript{human}/Asp\textsuperscript{mouse} substitution together with His762\textsuperscript{human}/Tyr\textsuperscript{mouse} affects inhibitor binding as the 173Asp\textsuperscript{mouse} and 762Tyr\textsuperscript{mouse} form a hydrogen bond and restricting the entrance to the active site. The corresponding residues, 173Phe\textsuperscript{human} and 762His\textsuperscript{human}, cannot create a similar hydrogen bond with each other. Tyr448\textsuperscript{human} and Asp180\textsuperscript{human} are both hydrogen-bonded to the inhibitor, but in mouse VAP-1 the corresponding residues are not at all interacting with the inhibitor. The Val209\textsuperscript{human}/Leu\textsuperscript{mouse} substitution will cause the conserved Tyr448\textsuperscript{human/mouse} into a slightly different conformation in the mouse VAP-1,
where it can hydrogen bond to Glu180\textsuperscript{mouse}, which is corresponding to Asp180\textsuperscript{human}.

Table 2. Residues lining the active site channel of VAP-1 from human, monkey, rat, and mouse that differ between the species. The residues causing significant differences in the channel properties are marked with an asterisk. The residues are colored by hydrophobicity (blue = most hydrophobic and red = most hydrophilic). (Publication III, Table I)

<table>
<thead>
<tr>
<th>Residue number</th>
<th>Human</th>
<th>Monkey</th>
<th>Rat</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chain A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>173*</td>
<td>Phe</td>
<td>Phe</td>
<td>Thr</td>
<td>Asp</td>
</tr>
<tr>
<td>177*</td>
<td>Leu</td>
<td>Leu</td>
<td>Gln</td>
<td>Gln</td>
</tr>
<tr>
<td>180*</td>
<td>Asp</td>
<td>Asp</td>
<td>Gln</td>
<td>Glu</td>
</tr>
<tr>
<td>210*</td>
<td>Thr</td>
<td>Thr</td>
<td>Lys</td>
<td>Thr</td>
</tr>
<tr>
<td>212</td>
<td>Thr</td>
<td>Asp</td>
<td>Thr</td>
<td>Thr</td>
</tr>
<tr>
<td>239</td>
<td>Phe</td>
<td>Phe</td>
<td>Tyr</td>
<td>Tyr</td>
</tr>
<tr>
<td>388</td>
<td>Gly</td>
<td>Gly</td>
<td>Ser</td>
<td>Ser</td>
</tr>
<tr>
<td>395</td>
<td>Thr</td>
<td>Thr</td>
<td>Ser</td>
<td>Ser</td>
</tr>
<tr>
<td>425</td>
<td>Ile</td>
<td>Ile</td>
<td>Leu</td>
<td>Leu</td>
</tr>
<tr>
<td>761*</td>
<td>Ser</td>
<td>Ser</td>
<td>Thr</td>
<td>Ala</td>
</tr>
<tr>
<td>Chain B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>447*</td>
<td>Leu</td>
<td>Leu</td>
<td>Phe</td>
<td>Phe</td>
</tr>
</tbody>
</table>
Figure 11. The active site cavity in mammalian VAP-1. A) The shape of the active site cavity in human, monkey, rat, and mouse VAP-1. B) Arm I (blue) from the other subunit of the dimer is lining the active site cavity and the Leu447human/Phe147mouse substitution in the rodents clearly limits the width of the active site channel in mouse and rat VAP-1. The residues that differ are shown as sticks; human (blue), monkey (green), rat (yellow) and mouse (magenta). C) Differences affecting the binding of inhibitor 13 in hVAP-1 compared with mouse VAP-1. (Figure adapted from Publication III, Figure 1 and Publication II, Figure 4.)

5.4 Evolution and functional classification of CAOs (IV)

5.4.1 General topology of the CAO phylogenetic tree (IV)

Phylogenetic trees were inferred using MEGA5, with ML and NJ methods. In total, 245 sequences from 78 species were used for the analysis. The ML and NJ trees are congruent, showing 3 distinct branches with bootstrap support ranging from 93% to 99% (Figure 12). Each of the three branches contain a different member of the CAO family with DAO proteins grouped in one branch, RAO proteins in another branch and VAP-1 and SAO proteins grouped together in the same branch. VAP-1 and SAO group together due to their high sequence identity of 84 to 92%. The branch lengths in Figure 12 are scaled to show relative evolutionary distance. The distances of the three branches show that RAO and VAP-1/SAO proteins are more closely related, while DAO presents a larger evolutionary distance to the rest of the proteins. The 3D multivariate plot generated is also congruent with the phylogenetic tree of the CAOs (Figure 12B).
Figure 12. Phylogenetic analysis of the CAOs. A) Maximum Likelihood tree based on JTT matrix-based model. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. Bootstrap values are shown to each main branch. B) Multivariate plot reflect the data for the phylogenetic tree. (Publication IV, Figure 2)

5.4.2 New insights into the classification of CAOs (IV)

CAOs have a highly conserved motif in the active site: Thr/Ser-X1-X2-Asn-Tyr-Asp/Glu (Klinman, 1996). Based on the phylogenetic tree, protein sequences in the DAO branch have Tyr in position X2, protein sequences in the RAO branch have Gly and protein sequences in the VAP-1 and SAO clade have a Leu in the corresponding X2 position (Table 3). Furthermore, analysis of the gene and sequence information of the VAP-1 and SAO proteins show that there is a clear division among the proteins in the VAP-1/SAO clade based on their residue in position X1. The proteins have either a Leu or a Met in position X1 and the two groups are actually coming from different genes (Figure 13). A multiple sequence alignment and phylogenetic trees with the proteins with Leu in position X1 marked as VAP-1 (AOC3) and proteins with Met in position X1 marked as SAO (AOC4) shows a clear divergence between the AOC3 and the
AOC4 gene product. Even though there is a clear division in the majority of the VAP-1 and SAO proteins, some SAO proteins (from dog, panda, water buffalo, cattle and bison) group together with VAP-1 in the multivariate 3D plot (Figure 13B).

Table 3. The active site motif in the different CAOs.

<table>
<thead>
<tr>
<th></th>
<th>Thr/Ser</th>
<th>X1</th>
<th>X2</th>
<th>Asn</th>
<th>TPQ</th>
<th>Asp</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAO</td>
<td>Thr</td>
<td>Val</td>
<td>Tyr</td>
<td>Asn</td>
<td>Tyr</td>
<td>Asp</td>
</tr>
<tr>
<td>RAO</td>
<td>Ser</td>
<td>Val</td>
<td>Gly</td>
<td>Asn</td>
<td>Tyr</td>
<td>Asp</td>
</tr>
<tr>
<td>VAP-1</td>
<td>Thr</td>
<td>Leu</td>
<td>Leu</td>
<td>Asn</td>
<td>Tyr</td>
<td>Asp</td>
</tr>
<tr>
<td>SAO</td>
<td>Thr</td>
<td>Met</td>
<td>Leu</td>
<td>Asn</td>
<td>Tyr</td>
<td>Asp</td>
</tr>
</tbody>
</table>
Figure 13. Phylogenetic analyses of VAP-1 and SAO proteins. A) The phylogenetic tree is inferred using Maximum Likelihood method based on the JTT matrix-based model. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. Last common ancestor marked with diamond. Bootstrap values are displayed in green. B) The multivariate plot confirms the division of VAP-1 and SAO proteins. (Publication IV, Figure 5)
5.5 VAP-1 to RAO mutations (I, IV)

The phylogenetic study confirmed that the CAOs can be classified based on the residues in the conserved active site motif, and that the residue in position X2 can be used to discriminate between the different CAOs (Table 3 & Figure 14). The active site close to TPQ is highly conserved. It is known that the CAOs have differences in their substrate preferences and the residue in position X2 is one of the reasons for the differences in substrate specificity. By experimentally mutating four residues in the VAP-1 active site to the corresponding ones in RAO (Met211Val, Thr212Ala, Tyr394Asn, and Leu469Gly) we could show that VAP-1 gets the substrate preferences of RAO. The mutations Leu469Gly and Met211Val especially affect the shape and size of the cavities. Leu469Gly mutation has the largest effect on the enzymatic properties and increases the oxidation of benzylamine (BZ) and 2-phenylethylamine (PEA) about 10-fold. In addition, the Leu469Gly mutant protein is able to oxidize p-tyramine (TYR) in contrast to WT VAP-1. The Met211Val mutation causes the active site to connect to the water channel instead of the active site channel. The mutational studies provide insight to the active site and function of RAO until a crystal structure is determined.
Figure 14. The CAO active sites with TPQ. Residues that are conserved in all CAOs are shown in white and non-conserved but similar residues are shown in light orange. A) DAO residues are shown in green. B) RAO residues are shown in pink. C) VAP-1 residues are shown in blue. D) SAO residues are shown in yellow. The conserved active site motif can be used as a basis for classification of the CAOs. Residues in position X1 in the active site motif are shown in brown and residues in position X2 are shown in dark blue. (Publication IV, Figure 6)
6. DISCUSSION

Currently there is a need for development of new types of medication against inflammatory and vascular diseases in the world. The amine oxidase involvement in human pathophysiological conditions has been known for decades (Boomsma et al., 2003) and its potential as a drug target in inflammatory diseases was noted shortly after the cloning and characterization of VAP-1 (Smith et al., 1998). As VAP-1 is involved in leukocyte transmigration to sites of inflammation it is possible to alleviate inflammatory conditions by blocking the adhesive and enzymatic function of VAP-1. VAP-1 is, therefore, a promising drug target. The results of these studies revealed a new mode of VAP-1 inhibition and molecular information important to the field of CAO research.

6.1 VAP-1, a challenging crystallographic target

In this study, five structures of hVAP-1 were determined by X-ray crystallography. The structures are overall similar to other reported CAO structures with a dimer as the biological unit and the monomer comprised of three domains (D2, D3 and D4), but they reveal new and interesting information. VAP-1 has proven to be a challenging crystallographic target with fragile and anisotropic crystals resulting in low-resolution structures. Before this study, there were only four crystal structures of mammalian CAOs available in complex with an inhibitor, hVAP-2HP complex (Jakobsson et al., 2005), bSAO in complex with clonidine (Holt et al., 2008), and DAO in complex with berenil and pentamidine (McGrath et al., 2009). Lunelli and coworkers have reported that deglycosylation was necessary to grow crystals of bSAO (Calderone et al., 2003). Here, we managed to grow crystals without deglycosylating the protein, but the crystals grew slowly, were anisotropic, extremely fragile and radiation-sensitive, which made the data collection challenging. The resolution of the new structures is between 2.60 and 3.10 Å, but the electron density is good throughout the structures. The 2F₀-Fᵡ maps together with the omit maps of the important regions clearly show the orientation of TPQ, the inhibitors and the side chain conformations of other important residues. For the inhibitor complex structures, corrections for anisotropy during data processing was especially important, as the effective resolution along the 6-fold axis was about 3.9 Å, while the effective resolution along the perpendicular directions was better than 3.0 Å.
Here we have determined the structure of cleaved human sVAP-1 for the first time, and two imidazole molecules from the crystallization buffer were bound in the protein. The sVAP-1 structures demonstrate the flexibility of TPQ, which was found in two different conformations, active off-copper and inactive on-copper, even though the crystals were grown in similar conditions. In the inactive on-copper TPQ conformation, imidazole makes a hydrogen bond to TPQ similarly as the imidazole in the active site of *Pichia Pastoris* CAO (PDB code 1RKY) (Duff et al., 2004) and (PDB code 1W7C) (Duff et al., 2006) and the imidazolidine ring of clonidine in the bSAO structure (Holt et al., 2008) (Figure S5 in Supporting Information in I). The other structure, where the TPQ is in active off-copper conformation and covalently bound to the imidazole, shows resemblance to the hVAP-1-2HP-complex (PDB code 2C11) (Jakobsson et al., 2005) (Figure S5 in Supporting Information in I).

### 6.2 Secondary imidazole binding site

It was experimentally shown that a 100 mM concentration of imidazole inhibits 93% of the VAP-1 activity. In addition to the TPQ-bound imidazole the sVAP-1 structures revealed a second imidazole binding site in the active site channel. The second imidazole molecule bound in the channel is hydrogen bonding to Thr212 and Tyr394. This secondary imidazole binding site in hVAP-1 seems to be different from the allosteric imidazoline binding site suggested for bSAO by kinetic studies performed by Holt and coworkers (Holt et al., 2008), because the corresponding residue to Tyr394 is Phe393 in bSAO, and Phe lacks the hydroxyl group of Tyr that binds the second imidazole molecule. With the help of the new sVAP-1 structures, the previously published VAP-1 structure (PDB code 1US1) (Airenne et al., 2005) could be re-evaluated and it turned out that an imidazole molecule can be built close to the TPQ. The imidazole bound in the active site channel disproves the prediction that Thr212 would be O-glycosylated (Airenne et al., 2005). These results, and the fact that an inhibitory effect of imidazole has previously been reported (Kelly et al., 1981), show the importance of excluding imidazole from the crystallization setup of CAO-inhibitor complexes.

### 6.3 VAP-1 old target, new inhibition mode

After the discovery of the secondary imidazole binding site in the active site channel, the idea of targeting the channel with small molecular inhibitors was raised. The majority of the earlier inhibitors for VAP-1 have been suicide
inhibitors like 2HP, which bind covalently to TPQ. Irreversible binding is not a desirable characteristic for a drug for human use (Palfreyman et al., 1994). A drug for human use should be removable, and the target activity should be regained within a short period of time. Therefore, a novel set of pyridazinone inhibitors targeted to the active site channel were designed and synthesized. The inhibitors showed great potency against hVAP-1 (IC$_{50}$ values of 26-250 nM), and they were also specific for hVAP-1 over MAOs and DAO. During the recent years the idea of reversible inhibitors for CAOs has evolved and BSAO and hDAO have been crystallized together with reversible inhibitors (Holt et al., 2008; McGrath et al., 2009).

The crystal structure of the VAP-1 inhibitor complexes showed that the inhibitors 6, 7 and 13 successfully bind noncovalently in the active site channel close to the secondary imidazole binding site, which is completely different from the complex structure of hVAP-1 and 2HP (Jakobsson et al., 2005). The binding of the inhibitors do not cause any major changes in the conformation of the residues in the active site channel compared to the native structure of VAP-1, except for Phe173 that has taken an alternative conformation to allow passage and create additional space for the inhibitors to bind. The phenyl ring of Phe389 has also rotated to make more favorable interactions to inhibitors 6 and 7. The binding of these inhibitors block the entrance and hinder any ligand of entering the active site.

Similarly, like the second imidazole molecule in VAP-1, clonidine in bSAO (Lunelli et al., 2005), berenil and pentamidine (McGrath et al., 2009) inhibitors bind noncovalently to DAO, but superposition of the structures show that the pyridazinone inhibitors bind further out in the active site channel than the other inhibitors (Figure 3 in I). The closest point of contact to TPQ in the berenil-hDAO complex is 4.5 Å, in the pentamidine-hDAO complex it is 4.0 Å, in the pyridazinone-VAP-1 complexes the distance to TPQ is 6.1-6.9 Å, while the secondary imidazole binding site lays 10 Å from TPQ (Figure 3 in I & Figure 9F). Arm I from the other monomer makes the entrance to the active site channel narrower in DAO than in VAP-1, which might affect the ligand binding properties (Figure 3 in I). The matter of reversible inhibitors for VAP-1 has subsequently been discussed by Bonaiuto and coworkers who recognized a synthetic polyamine as a reversible inhibitor that binds in the active site channel and blocks the entrance to TPQ (Bonaiuto et al., 2012), similarly to the pyridazinone inhibitors. The binding mode for the pyridazinone inhibitors is
also different from other recent computational studies, where docking and QSAR models of potential VAP-1 inhibitors have been published (Foot et al., 2012; Inoue et al., 2013a; Inoue et al., 2013b; Nurminen et al., 2010; Nurminen et al., 2011).

### 6.3.1 Molecular binding mode of the pyridazinone inhibitors

Due to the scaffold, the inhibitors show a similar binding mode with only minor differences in their hydrogen bonds, π-stacking, and hydrophobic interactions to VAP-1. There are hydrophobic interactions by Phe173, Leu177, Leu468, and Leu469 to the inhibitors. It has been shown that the enzyme substrate recognition step in VAP-1 is mainly controlled by hydrophobic interactions (Bonaiuto et al., 2010) and actually, the largest and most hydrophobic inhibitor, 13, shows the best binding. The second phenyl ring and the piperazine group of 13 accounts for its better binding because the lack of these groups in inhibitor 7 leads to lower potency. Arm I from the other monomer is apparently important for the binding of the inhibitors as Tyr448B makes a hydrogen bond with all inhibitors.

The side chain of Thr212 is flexible and makes a water mediated hydrogen bond to the inhibitors in all A chains and in the other chains it is not interacting with the inhibitors but is hydrogen bonded to Arg216. However, Thr212 is also involved in the binding of the second imidazole, and the corresponding residue Asp186 in DAO has been shown to bind the second amine of the diamine substrates (McGrath et al., 2009), and therefore, this position seems to be of special importance in ligand binding. Actually, the only substitution between the cynomolgus monkey and the human is this residue. However, the substitution Thr212\textsuperscript{human}/Asn\textsuperscript{monkey} does not cause any difference in the binding of the inhibitors, as the inhibitors bind both proteins equally well because Asn212\textsuperscript{monkey} can interact with the inhibitors.

### 6.3.2 Species specific binding of the pyridazinone inhibitors

Even though 6, 7, and 13 are potent hVAP-1 inhibitors, they are surprisingly weak inhibitors of mouse VAP-1 activity. In our attempts to explain the species-specific binding properties of the pyridazinone inhibitors, we made homology models of monkey, mouse and rat VAP-1 based on the crystal structure of hVAP-1. Based on the models we could not find any prominent differences between the rodent and primate VAP-1 in the active site near TPQ. Marti and
coworkers could not either find any differences close to TPQ in their previous homology models of the mouse VAP-1 (Marti et al., 2004). This is in line with the experimental results from this study, as the activity measurements with the control compound, a hydrazine derived inhibitor (Nurminen et al., 2011) which binds to TPQ, inhibits both rodent and primate VAP-1. However, when we extended the analysis to the active site channel and the region where the second imidazole and the inhibitors bind, we could find significant differences.

From the comparison of the active site shape in primate and rodent VAP-1 it was seen that the active site of rodent VAP-1 is narrower than the active site in primates. Especially, the substitution of Leu447B/Phe\textsuperscript{rat/mouse} in Arm I, which reaches the active site channel from the other monomer, clearly restricts the width of the channel and the space for the inhibitors. It is thought that Arm I, is important for the dimer stability and regulation of substrate specificity in the CAOs (Klema & Wilmot, 2012). Here we can clearly see that the substitution of a smaller Leu in the primate VAP-1 to a larger Phe in the rodents is important for the ligand to access the active site, and therefore, we suggest that this residue can function as a porter residue in the rodent VAP-1. This suggestion is supported by the fact that Inoue and coworkers also identified the Leu447B/Phe\textsuperscript{rat} substitution to cause species specific binding differences of their thiazole derivative inhibitors, which bind TPQ but due to their size extends out to the active site channel (Inoue et al., 2013a; Inoue et al., 2013b).

Based on our modelled mouse VAP-1 there are, in addition to the shape differences of the active sites, less favorable interactions between the mouse VAP-1 and inhibitor 13 than with hVAP-1. These differences can explain the poor inhibitor potency against the mouse VAP-1. The Phe173/Asp\textsuperscript{mouse} substitution together with His762/Tyr\textsuperscript{mouse} affects inhibitor binding, as the interaction between Asp and Tyr in the mouse VAP-1 restricts the entrance to the active site. In hVAP-1 Tyr448B and Asp180 are both involved in hydrogen bonding to the inhibitor, while in mouse VAP-1, these interactions are missing. The active site channel of hVAP-1 is more hydrophobic than mouse VAP-1 because of Phe173/Asp\textsuperscript{mouse} and Leu177/Gln\textsuperscript{mouse} substitutions in which hydrophobic residues are changed to a charged and a polar residue in the mouse protein. As the pyridazinone inhibitors are rather large and hydrophobic, the interactions are not as favorable in the mouse VAP-1 as in the hVAP-1.
6.4 The evolution of CAOs

The phylogenetic tree of the CAOs contains three major branches. The distances of the three branches show that RAO, VAP-1, and SAO, proteins are more closely related, while DAO presents a larger evolutionary distance to the rest of the proteins. The distances also show that VAP-1 and SAO proteins are the closest relatives of the CAOs, and that they seem to have diverged more recently than RAO and DAO. The multivariate analysis confirms these results, as the proteins cluster together in a similar way in the 3D plots. The 3D multivariate analysis represents a nice support and validation tool for the phylogenetic studies, as the plot shows the relation of the individual clusters. It is not surprising that DAO is most distantly related in the CAO family, because the DAO encoding gene, AOC1, is not linked to the other genes (Schwelberger, 2010).

6.4.1 Classification of CAOs, VAP-1 and SAO

CAOs are currently classified into EC 1.4.3.21 (RAO, VAP-1, SAO) and EC 1.4.3.22 (DAO) families. The results from the phylogenetic study of the large set of CAO sequences show the importance of the Thr/Ser-X1-X2-Asn-Tyr-Asp/Glu active site motif and confirm that positions X1 and X2 could be used to classify CAOs into AOC1-4 sub families. Based on the phylogenetic tree, all protein sequences in the DAO branch have Tyr in position X2, all protein sequences in the RAO branch have Gly, and all protein sequences in the VAP-1 and SAO clade have a Leu in the corresponding X2 position. Therefore, the results support the idea that the residue in position X2 can be used as criteria to differentiate between mammalian CAO proteins. Even though the mammalian CAOs can easily be classified based on the residue in position X2 of the active site motif, a correct and formal method to distinguish between VAP-1 and SAO proteins has been missing and the majority of SAO proteins is annotated as membrane primary amine oxidase-like. Here we found a clear division among the proteins in the VAP-1/SAO clade based on their residue in the position X1. Sequence alignment and the phylogenetic tree reveal that VAP-1 proteins have a Leu in position X1, while SAO proteins have a Met in position X1 in the active site motif, and therefore, we suggest that VAP-1 and SAO can be classified based on the residue in position X1.

Regarding the closely related VAP-1 and SAO, it seems that they have evolved differently in individual species due to varying evolutionary pressure. In some
species, the SAO proteins seems to be the ancestral protein and duplication has
given origin to VAP-1 (rabbit and lemur), while in other species, it is the
opposite with VAP-1 giving origin to SAO (nine-banded armadillo and chinese
tree shrew). It also varies among the species when the divergence between VAP-
1 and SAO occurred, and not all species have both VAP-1 and SAO proteins. It
is possible that the mutation that gave origin to the stop codon in human SAO
was favored because the soluble form of VAP-1 (sVAP-1) can substitute SAO. In
dog, the SAO protein is an isoform from the AOC3 gene, while in panda the
sequence is from the AOC3 gene but contains a Met in position X1 that
according to the classification rules makes it VAP-1. It might, however, be that
the divergence between VAP-1 and SAO into two distinct proteins is still
occurring in the dog and the bovine, which represents outliers in the study. The
mutation that causes the change from Leu to Met, and makes the difference
between VAP-1 and SAO, is only one base pair in the codon. Moreover, dog
VAP-1 and SAO proteins might give important insight into the evolution of the
proteins, as there is positive selection for both isoforms from the same gene.

6.5 VAP-1 to RAO mutations

Kaitaniemi and coworkers have previously shown that a triple mutant
(Mel211Val/Tyr394Asn/Leu469Gly) of VAP-1 where the three residues in the
active site are changed to the corresponding ones in RAO affect the substrate
preference profile (Kaitaniemi et al 2009). In this study, these residues and
Thr212 were individually mutated and the results showed that Leu469 and
Met211 are important for VAP-1 substrate recognition. The absence of the gate
the Leu469/Gly mutation together with the Thr212Ala and Met211Val
mutations makes the active site channel more open and the substrates can easily
reach and bind TPQ (Figure 7B in I), hence the improved oxidation of BZ and
PEA. However, it seems that loss of Met211 and hydrophobic side chains makes
the correct positioning of the small methylamine (MA) difficult. Met211 and
Leu469 have previously been reported flexible and in different conformations
(Figure 8 in I) (Lunelli et al., 2005; McGrath et al., 2009; Nurminen et al 2010),
which supports the idea that they are important in substrate acceptance,
preference and/or positioning. Met211Val also cause changes in the active site
channel so that the primary active site is connected to a water channel instead of
the active site channel.
7. CONCLUSIONS

In summary, these results will altogether aid future development and design of therapeutics for inflammatory diseases, and especially, VAP-1-associated diseases. The identification of a secondary binding site in the active site channel, together with the detailed binding mode revealed by crystal structures of the novel pyridazinone inhibitors, will further enable the development of new type of pyridazinone inhibitors, as well as, other completely different reversible inhibitors. Anti-VAP-1 antibodies might be closer to the market, but the small molecular inhibitors compose an attractive alternative as they can simultaneously inhibit the adhesive and enzymatic activity of VAP-1 and, therefore, inhibit both the transmigration of leukocytes and the proinflammatory effects of VAP-1 activity.

The new structural information of the VAP-1 active site, provided by X-ray structures and homology models, is of importance in drug design. The active site of enzymes and their known ligands can be utilized as a starting point for rational drug design, as analogues of known substrates and inhibitors can be designed and developed (Salmi & Jalkanen, 2005). Available crystal structures will not only aid in the planning and development of new inhibitors, but will also aid in the development of PET-tracers and other diagnostic tools.

The results of this study also draw attention to the importance of acknowledging species specific differences in the drug development. Here we have clear differences in the binding of the pyridazinone inhibitors to the rodent and primate proteins. As rodents are often used for \textit{in vivo} testing of candidate drugs, it is especially important to acknowledge, that there can be small but crucial species specific differences in the proteins even though the sequence identity is rather high.

The results from the phylogenetic study confirm that the CAOs can be classified based on their residue in position X2 in the Thr/Ser-X1-X2-Asn-Tyr-Asp/Glu active site motif. We could also confirm that the VAP-1 and SAO sequences can be distinguished by the residue in position X1. These results will aid in the classification of new CAO sequences, and also in the reclassification of wrongly annotated sequences.
8. FUTURE PERSPECTIVES

The results from this study will be of use in the development of new and improved drugs in inflammatory diseases. One way to follow up on this study would be to improve the rodent VAP-1 inhibition of the pyridazinone inhibitors. However, the excellent specificity for hVAP-1 would need to be contained and that seems challenging, because the residues differing between the rodent and the primate protein are well-distributed in the active site channel. The differences affect the binding of several functional groups of the inhibitors. As there are significant differences between the species throughout the binding site in the active site channel, it is likely that specificity for the human protein is lost if the specificity for the rodent protein is improved. Other modifications to the inhibitors could also increase their promiscuity for other CAOs or even introduce toxicological liabilities that comprise their further development. Therefore, it is suggested that the species specific binding properties of these pyridazinone inhibitors are acknowledged and other methods than in vivo rodent testing are worth considering for future studies. Suitable approaches could include the use of human in vivo transgenic mice models, and other in vitro or ex vivo human disease-models. Nonhuman primate disease models can be used for toxicological and efficacy studies where suitable models exist and new human disease models could be developed (Peltz, 2013; Misharin et al., 2010; Imam et al., 2013).

The understanding of VAP-1 and its molecular mechanisms and functionalities are highly desirable as VAP-1 is such a promising drug target in inflammatory diseases. Further characterization of the VAP-1 counter-receptors Siglec-9 and Siglec-10, will reveal more information about their interaction with VAP-1. The determination of the precise interaction site and mode will help to improve existing VAP-1 inhibitors and aid in the planning of new inhibitors. We studied the evolution of the different CAOs and the next step would be to do a protein specific phylogenetic study, to analyze how the different proteins have evolved in different organisms and to pinpoint species specific differences that could be involved in substrate recognition and binding.
9. REFERENCES


Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) Basic local alignment search tool. *Journal of Molecular Biology*, 215(3), 403-410


Hartmann, C., & Klinman, J. P. (1991) Structure-function studies of substrate oxidation by bovine serum amine oxidase: Relationship to cofactor structure and mechanism. *Biochemistry, 30*(18), 4605-4611


60


61


Maula, S. M., Salminen, T., Kaitaniemi, S., Nymalm, Y., Smith, D. J., & Jalkanen, S. (2005) Carbohydrates located on the top of the "cap" contribute to the adhesive and
enzymatic functions of vascular adhesion protein-1. *European Journal of Immunology, 35*(9), 2718-2727


McGrath, A. P., Caradoc-Davies, T., Collyer, C. A., & Guss, J. M. (2010b) Correlation of active site metal content in human diamine oxidase with trihydroxyphenylalanine quinone cofactor biogenesis. *Biochemistry, 49*(38), 8316-8324


Noda, K., Miyahara, S., Nakazawa, T., Almulki, L., Nakao, S., Hisatomi, T., She, H., Thomas, K. L., Garland, R. C., Miller, J. W., Gragoudas, E. S., Kawai, Y., Mashima,


quinoenzyme: copper amine oxidase of *Esterichia coli* at 2 Å resolution. *Structure* 3(11), 1171-1184


Salmi, M., Hellman, J., & Jalkanen, S. (1998) The role of two distinct endothelial molecules, vascular adhesion protein-1 and peripheral lymph node addressin, in the binding of lymphocyte subsets to human lymph nodes. *Journal of Immunology*, 160(11), 5629-5636


Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., & Kumar, S. (2011) MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Molecular Biology and Evolution, 28*(10), 2731-2739


tumor endothelium in human hepatocellular carcinoma. *Journal of Immunology, 160*(8), 3978-3988


Eva Bligt-Lindén

VAP-1 as drug target in inflammation: Structural features determining ligand interactions

2015

ISBN 978-952-12-3306-7